Sitagliptin Phosphate (50mg) & Metformin HCl (500mg) – Uses, Benefits, and Dosage

Mar 04, 2025

Introduction

GLISITAPTIN M 50/500 is a combination medication consisting of two active ingredients: Sitagliptin Phosphate and Metformin Hydrochloride (HCI). This medication is used primarily for the management of type 2 diabetes mellitus (T2DM). Both Sitagliptin Phosphate and Metformin are commonly prescribed individually to help control blood sugar levels in diabetic patients, but the combination of these two drugs offers a more effective and convenient way to manage the condition.

Type 2 diabetes is a chronic condition characterized by elevated blood glucose levels due to insulin resistance or insufficient insulin production by the pancreas. Proper management of blood sugar levels is critical to prevent long-term complications, such as cardiovascular disease, kidney damage, neuropathy, and retinopathy. GLISITAPTIN M 50/500 combines the benefits of both medications to help patients control their blood sugar levels more effectively.

Key Ingredients and Their Functions

  • Sitagliptin Phosphate (50 mg)
    Sitagliptin Phosphate is a member of a class of medications known as DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). It works by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones like GLP-1 (glucagon-like peptide-1). Incretin hormones are released from the intestines after eating and help regulate blood sugar by stimulating insulin release from the pancreas and reducing glucagon secretion. By inhibiting DPP-4, Sitagliptin increases the levels of these hormones, enhancing the body’s ability to lower blood glucose after meals.

  • Metformin Hydrochloride (500 mg)
    Metformin is one of the most commonly prescribed medications for type 2 diabetes. It works primarily by decreasing hepatic glucose production (the production of glucose by the liver) and increasing insulin sensitivity in the peripheral tissues, especially muscle cells. Metformin also improves glucose uptake and utilization, helping to lower blood sugar levels. Unlike some other diabetes medications, Metformin does not typically cause weight gain or increase the risk of hypoglycemia (dangerously low blood sugar levels).

The combination of these two drugs offers a complementary mechanism of action that targets multiple pathways involved in blood sugar regulation.

How Does GLISITAPTIN M 50/500 Work?

GLISITAPTIN M 50/500 works by utilizing the combined effects of Sitagliptin Phosphate and Metformin to reduce blood glucose levels in people with type 2 diabetes.

  • Sitagliptin Phosphate enhances insulin release after meals by increasing incretin hormone levels. These hormones act to boost insulin production and suppress glucagon, which reduces glucose production by the liver.
  • Metformin helps lower blood sugar levels by reducing glucose production in the liver and improving insulin sensitivity in muscles and fat tissues, enabling more efficient glucose uptake and utilization.

The combination of these actions allows for more effective blood glucose control than either medication used alone. This makes GLISITAPTIN M 50/500 an essential medication for many patients with type 2 diabetes, especially when other treatment options have proven inadequate or difficult to tolerate.

Benefits of GLISITAPTIN M 50/500

  1. Improved Blood Sugar Control
    One of the primary benefits of GLISITAPTIN M 50/500 is its ability to provide more consistent and effective blood sugar control. By combining the actions of Sitagliptin and Metformin, this medication works through multiple pathways to reduce blood glucose levels, particularly after meals when blood sugar tends to spike.

  2. Weight Management
    Metformin, one of the components of GLISITAPTIN M 50/500, is known to have a neutral or even beneficial effect on weight. Unlike some diabetes medications that can cause weight gain, Metformin is associated with weight stability or modest weight loss. This can be particularly beneficial for patients who are overweight or obese, as weight management is an important aspect of diabetes control.

  3. Lower Risk of Hypoglycemia
    Another significant benefit of GLISITAPTIN M 50/500 is its relatively low risk of causing hypoglycemia (low blood sugar levels). This is especially important for people with diabetes, as episodes of hypoglycemia can lead to symptoms such as dizziness, confusion, shakiness, and even loss of consciousness. Since neither Sitagliptin nor Metformin causes a direct increase in insulin levels, the risk of hypoglycemia is minimal when taken as directed.

  4. Convenient Combination
    Instead of taking two separate medications, GLISITAPTIN M 50/500 combines Sitagliptin and Metformin into one tablet, making it easier for patients to manage their diabetes treatment. This improves patient adherence to the medication regimen and helps ensure more consistent blood glucose control.

  5. Cardiovascular Benefits
    Some studies have suggested that DPP-4 inhibitors like Sitagliptin may have cardiovascular benefits, although more research is needed. In patients with type 2 diabetes, cardiovascular health is a major concern, as they are at increased risk for heart disease. Therefore, the potential cardiovascular benefits of Sitagliptin may be an additional advantage of this medication.

Dosage and Administration

The typical dose of GLISITAPTIN M 50/500 is one tablet once or twice daily, depending on the patient's individual needs and the doctor’s recommendations. The medication should be taken with food to minimize the risk of gastrointestinal side effects, such as nausea and upset stomach, which are common with Metformin.

Patients should follow their healthcare provider's instructions regarding dosage, and the dose may need to be adjusted based on blood glucose levels, renal function, and other factors.

Side Effects of GLISITAPTIN M 50/500

Like any medication, GLISITAPTIN M 50/500 may cause side effects, although not everyone will experience them. Some common side effects include:

  • Gastrointestinal Issues

    • Nausea
    • Vomiting
    • Diarrhea
    • Abdominal pain
    • Loss of appetite These side effects are more commonly associated with Metformin and usually subside after the body adjusts to the medication.
  • Low Blood Sugar (Hypoglycemia)
    Although the risk of hypoglycemia with GLISITAPTIN M 50/500 is low, it can occur, especially if the medication is taken in conjunction with other diabetes medications that increase insulin production, such as sulfonylureas. Symptoms of hypoglycemia include shakiness, dizziness, sweating, and confusion.

  • Lactic Acidosis (Rare but Serious)
    A rare but serious side effect of Metformin is lactic acidosis, a condition in which lactic acid builds up in the bloodstream. This can lead to symptoms such as rapid breathing, muscle pain, tiredness, and stomach discomfort. Lactic acidosis is more likely to occur in people with impaired kidney function or those who are dehydrated, so it's essential to have regular kidney function tests while on this medication.

  • Upper Respiratory Tract Infections
    Sitagliptin has been associated with an increased risk of respiratory tract infections, including sore throat, nasal congestion, and cough.

  • Skin Reactions
    Some people may develop skin reactions, including rash, itching, or swelling, though these are uncommon.

Precautions and Warnings

Before starting GLISITAPTIN M 50/500, it’s important to inform the healthcare provider of any existing medical conditions, particularly:

  • Kidney Disease
    Metformin is primarily excreted through the kidneys, so patients with impaired renal function should not take GLISITAPTIN M 50/500. Kidney function should be assessed before starting treatment and periodically thereafter.

  • Liver Disease
    Liver impairment can affect how Sitagliptin and Metformin are metabolized and eliminated from the body, so caution is needed in patients with liver disease.

  • Alcohol Consumption
    Excessive alcohol intake can increase the risk of lactic acidosis and should be avoided while taking Metformin.

  • Pregnancy and Breastfeeding
    GLISITAPTIN M 50/500 is generally not recommended during pregnancy, especially in the first trimester. It’s important to discuss potential risks with a healthcare provider before using this medication during pregnancy or breastfeeding.

Price and Availability

The price of GLISITAPTIN M 50/500 can vary depending on the region and the pharmacy. In general, combination medications like this one are priced higher than individual medications due to their convenience and efficacy. However, the cost may be offset by insurance coverage or patient assistance programs offered by pharmaceutical companies. For the most accurate price, it’s advisable to check with local pharmacies.

Conclusion

GLISITAPTIN M 50/500 is an effective combination therapy for managing type 2 diabetes, offering improved blood glucose control through the combined actions of Sitagliptin Phosphate and Metformin Hydrochloride. With its ability to manage blood sugar levels while minimizing the risk of hypoglycemia and promoting weight management, it is a popular choice among healthcare providers for treating type 2 diabetes. As with any medication, it's important for patients to follow their healthcare provider's guidance to minimize side effects and achieve the best results in managing their diabetes.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW

SHARE WITH